;PMID: 10661623
;source_file_1361.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..129] = [t:39..129]
;2)section:[e:133..252] = [t:133..252]
;3)section:[e:256..336] = [t:256..336]
;4)sentence:[e:340..507] = [t:340..507]
;5)sentence:[e:508..623] = [t:508..623]
;6)sentence:[e:624..780] = [t:624..780]
;7)sentence:[e:781..841] = [t:781..841]
;8)sentence:[e:842..900] = [t:842..900]
;9)sentence:[e:901..1100] = [t:901..1100]
;10)sentence:[e:1101..1231] = [t:1101..1231]
;11)sentence:[e:1232..1370] = [t:1232..1370]
;12)sentence:[e:1371..1502] = [t:1371..1502]
;13)sentence:[e:1503..1668] = [t:1503..1668]
;14)sentence:[e:1669..1831] = [t:1669..1831]
;15)section:[e:1835..1880] = [t:1835..1880]

;section 0 Span:0..34
;Anal Cell Pathol  1999;19(1):39-46
(SEC
  (FRAG (NNP:[0..4] Anal) (NNP:[5..9] Cell) (NNP:[10..16] Pathol)
        (CD:[18..26] 1999;19-LRB-) (CD:[26..27] 1) (-RRB-:[27..28] -RRB-)
        (CD:[28..31] :39) (IN:[31..32] -) (CD:[32..34] 46)))

;sentence 1 Span:39..129
;K-ras2 activation and genome instability increase proliferation and size of
;FAP  adenomas.
;[39..45]:gene-rna:"K-ras2"
;[115..128]:malignancy:"FAP  adenomas"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (NN:[39..45] K-ras2) (NN:[46..56] activation))
      (CC:[57..60] and)
      (NP (NN:[61..67] genome) (NN:[68..79] instability)))
    (VP (VBP:[80..88] increase)
      (NP
        (NP (NN:[89..102] proliferation) (CC:[103..106] and)
            (NN:[107..111] size))
        (PP (IN:[112..114] of)
          (NP (NN:[115..118] FAP) (NNS:[120..128] adenomas)))))
    (.:[128..129] .)))

;section 2 Span:133..252
;Rapallo A, Sciutto A, Geido E, Orecchia R, Infusini E, Pujic N, d'Amore ES, 
;Monaco R, Risio M, Rossini FP, Giaretti W.
(SEC
  (FRAG (NNP:[133..140] Rapallo) (NNP:[141..142] A) (,:[142..143] ,)
        (NNP:[144..151] Sciutto) (NNP:[152..153] A) (,:[153..154] ,)
        (NNP:[155..160] Geido) (NNP:[161..162] E) (,:[162..163] ,)
        (NNP:[164..172] Orecchia) (NNP:[173..175] R,) (NNP:[176..184] Infusini)
        (NNP:[185..186] E) (,:[186..187] ,) (NNP:[188..193] Pujic)
        (NNP:[194..195] N) (,:[195..196] ,) (NNP:[197..204] d'Amore)
        (NNP:[205..207] ES) (,:[207..208] ,) (NNP:[210..216] Monaco)
        (NNP:[217..219] R,) (NNP:[220..225] Risio) (NNP:[226..228] M,)
        (NNP:[229..236] Rossini) (NNP:[237..239] FP) (,:[239..240] ,)
        (NNP:[241..249] Giaretti) (NNP:[250..252] W.)))

;section 3 Span:256..336
;Laboratory of Biophysics and Cytometry, National Cancer Institute, Genoa,
;Italy.
(SEC
  (FRAG (NN:[256..266] Laboratory) (IN:[267..269] of)
        (NNP:[270..280] Biophysics) (CC:[281..284] and)
        (NNP:[285..294] Cytometry) (,:[294..295] ,) (NNP:[296..304] National)
        (NNP:[305..311] Cancer) (NNP:[312..321] Institute) (,:[321..322] ,)
        (NNP:[323..328] Genoa) (,:[328..329] ,) (NNP:[330..335] Italy)
        (.:[335..336] .)))

;sentence 4 Span:340..507
;The possible role of K-ras2 mutations and aneuploidy toward increase of 
;proliferation and adenoma size in Familial Adenomatous Polyposis (FAP)
;adenomas  is not known.
;[361..367]:gene-rna:"K-ras2"
;[382..392]:variation-type:"aneuploidy"
;[431..438]:malignancy:"adenoma"
;[447..492]:malignancy:"Familial Adenomatous Polyposis (FAP) adenomas"
;[479..482]:malignancy:"FAP"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[340..343] The) (JJ:[344..352] possible) (NN:[353..357] role))
      (PP (IN:[358..360] of)
        (NP
          (NP
            (NP (NN:[361..367] K-ras2) (NNS:[368..377] mutations))
            (CC:[378..381] and)
            (NP (NN:[382..392] aneuploidy)))
          (PP (IN:[393..399] toward)
            (NP
              (NP (NN:[400..408] increase))
              (PP (IN:[409..411] of)
                (NP
                  (NP (NN:[413..426] proliferation))
                  (CC:[427..430] and)
                  (NP (NN:[431..438] adenoma) (NN:[439..443] size))))
              (PP (IN:[444..446] in)
                (NP
                  (NML
                    (NML (JJ:[447..455] Familial) (JJ:[456..467] Adenomatous)
                         (NN:[468..477] Polyposis))
                    (NML (-LRB-:[478..479] -LRB-) (NN:[479..482] FAP)
                         (-RRB-:[482..483] -RRB-)))
                  (NNS:[484..492] adenomas))))))))
    (VP (VBZ:[494..496] is) (RB:[497..500] not)
      (VP (VBN:[501..506] known)
        (NP-1 (-NONE-:[506..506] *))))
    (.:[506..507] .)))

;sentence 5 Span:508..623
;The present study addresses these issues by investigating 147  colorectal
;adenomas obtained from four FAP patients.
;[571..590]:malignancy:"colorectal adenomas"
;[610..613]:malignancy:"FAP"
(SENT
  (S
    (NP-SBJ (DT:[508..511] The) (JJ:[512..519] present) (NN:[520..525] study))
    (VP (VBZ:[526..535] addresses)
      (NP (DT:[536..541] these) (NNS:[542..548] issues))
      (PP (IN:[549..551] by)
        (S-NOM
          (NP-SBJ (-NONE-:[551..551] *))
          (VP (VBG:[552..565] investigating)
            (NP
              (NP (CD:[566..569] 147)
                 (JJ:[571..581] colorectal) (NNS:[582..590] adenomas))
              (VP (VBN:[591..599] obtained)
                (NP (-NONE-:[599..599] *))
                (PP (IN:[600..604] from)
                  (NP (CD:[605..609] four) (NN:[610..613] FAP)
                      (NNS:[614..622] patients)))))))))
    (.:[622..623] .)))

;sentence 6 Span:624..780
;The majority of adenomas  had size lower than or equal to 10 mm (86%), low
;grade dysplasia (63%), and were  preferentially located in the right colon
;(60%).
;[640..648]:malignancy:"adenomas"
;[695..714]:malignancy:"low grade dysplasia"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[624..627] The) (NN:[628..636] majority))
      (PP (IN:[637..639] of)
        (NP (NNS:[640..648] adenomas))))
    (VP
      (VP (VBD:[650..653] had)
        (NP
          (NP
            (NP (NN:[654..658] size))
            (NP
              (QP (JJR:[659..664] lower) (IN:[665..669] than) (CC:[670..672] or)
                  (JJ:[673..678] equal) (TO:[679..681] to) (CD:[682..684] 10))
              (NN:[685..687] mm)
              (PRN (-LRB-:[688..689] -LRB-)
                (NP (CD:[689..691] 86) (NN:[691..692] %))
                (-RRB-:[692..693] -RRB-))))
          (,:[693..694] ,)
          (NP
             (JJ:[695..698] low) (NN:[699..704] grade) (NN:[705..714] dysplasia)
            (PRN (-LRB-:[715..716] -LRB-)
              (NP (CD:[716..718] 63) (NN:[718..719] %))
              (-RRB-:[719..720] -RRB-)))))
      (,:[720..721] ,) (CC:[722..725] and)
      (VP (VBD:[726..730] were)
        (ADVP (RB:[732..746] preferentially))
        (VP (VBN:[747..754] located)
          (NP-1 (-NONE-:[754..754] *))
          (PP-LOC (IN:[755..757] in)
            (NP (DT:[758..761] the) (JJ:[762..767] right) (NN:[768..773] colon)))
          (PRN (-LRB-:[774..775] -LRB-)
            (NP (CD:[775..777] 60) (NN:[777..778] %))
            (-RRB-:[778..779] -RRB-)))))
    (.:[779..780] .)))

;sentence 7 Span:781..841
;Normal mucosa samples were  obtained from 19 healthy donors.
(SENT
  (S
    (NP-SBJ-1 (JJ:[781..787] Normal) (NN:[788..794] mucosa)
              (NNS:[795..802] samples))
    (VP (VBD:[803..807] were)
      (VP (VBN:[809..817] obtained)
        (NP-1 (-NONE-:[817..817] *))
        (PP (IN:[818..822] from)
          (NP (CD:[823..825] 19) (JJ:[826..833] healthy) (NNS:[834..840] donors)))))
    (.:[840..841] .)))

;sentence 8 Span:842..900
;Three synchronous adenocarcinomas were also  investigated.
;[860..875]:malignancy:"adenocarcinomas"
(SENT
  (S
    (NP-SBJ-1 (CD:[842..847] Three) (JJ:[848..859] synchronous)
              (NNS:[860..875] adenocarcinomas))
    (VP (VBD:[876..880] were)
      (ADVP (RB:[881..885] also))
      (VP (VBN:[887..899] investigated)
        (NP-1 (-NONE-:[899..899] *))))
    (.:[899..900] .)))

;sentence 9 Span:901..1100
;K-ras2 mutation spectrum was analysed by PCR and Sequence Specific 
;Oligonucleotide (SSO) hybridization, while flow cytometry (FCM) was used for 
;evaluating degree of DNA ploidy and S-phase fraction.
;[901..907]:gene-rna:"K-ras2"
;[1072..1078]:variation-type:"ploidy"
(SENT
  (S
    (NP-SBJ-2 (NN:[901..907] K-ras2) (NN:[908..916] mutation)
              (NN:[917..925] spectrum))
    (VP (VBD:[926..929] was)
      (VP (VBN:[930..938] analysed)
        (NP-2 (-NONE-:[938..938] *))
        (PP-MNR (IN:[939..941] by)
          (NP
            (NP (NN:[942..945] PCR))
            (CC:[946..949] and)
            (NP
              (NML
                (NML (NN:[950..958] Sequence) (JJ:[959..967] Specific)
                     (NN:[969..984] Oligonucleotide))
                (NML (-LRB-:[985..986] -LRB-) (NN:[986..989] SSO)
                     (-RRB-:[989..990] -RRB-)))
              (NN:[991..1004] hybridization))))
        (,:[1004..1005] ,)
        (SBAR-ADV (IN:[1006..1011] while)
          (S
            (NP-SBJ-1
              (NP (NN:[1012..1016] flow) (NN:[1017..1026] cytometry))
              (NP (-LRB-:[1027..1028] -LRB-) (NN:[1028..1031] FCM)
                  (-RRB-:[1031..1032] -RRB-)))
            (VP (VBD:[1033..1036] was)
              (VP (VBN:[1037..1041] used)
                (NP-1 (-NONE-:[1041..1041] *))
                (PP (IN:[1042..1045] for)
                  (S-NOM
                    (NP-SBJ (-NONE-:[1045..1045] *))
                    (VP (VBG:[1047..1057] evaluating)
                      (NP
                        (NP (NN:[1058..1064] degree))
                        (PP (IN:[1065..1067] of)
                          (NP
                            (NP (NN:[1068..1071] DNA) (NN:[1072..1078] ploidy))
                            (CC:[1079..1082] and)
                            (NP (NN:[1083..1090] S-phase)
                                (NN:[1091..1099] fraction))))))))))))))
    (.:[1099..1100] .)))

;sentence 10 Span:1101..1231
;Overall, incidences of  K-ras2 mutations, DNA aneuploidy and high S-phase
;values (>7.2%) were 6.6%, 5.4%  and 10.5%, respectively.
;[1125..1131]:gene-rna:"K-ras2"
;[1147..1157]:variation-type:"aneuploidy"
(SENT
  (S
    (ADVP (RB:[1101..1108] Overall))
    (,:[1108..1109] ,)
    (NP-SBJ
      (NP (NNS:[1110..1120] incidences))
      (PP (IN:[1121..1123] of)
        (NP
          (NP (NN:[1125..1131] K-ras2) (NNS:[1132..1141] mutations))
          (,:[1141..1142] ,)
          (NP (NN:[1143..1146] DNA) (NN:[1147..1157] aneuploidy))
          (CC:[1158..1161] and)
          (NP (JJ:[1162..1166] high) (NN:[1167..1174] S-phase)
              (NNS:[1175..1181] values)
            (PRN (-LRB-:[1182..1183] -LRB-)
              (VP (SYM:[1183..1184] >)
                (NP (CD:[1184..1187] 7.2) (NN:[1187..1188] %)))
              (-RRB-:[1188..1189] -RRB-))))))
    (VP (VBD:[1190..1194] were)
      (NP-PRD
        (NP (CD:[1195..1198] 6.6) (NN:[1198..1199] %))
        (,:[1199..1200] ,)
        (NP (CD:[1201..1204] 5.4) (NN:[1204..1205] %))
        (CC:[1207..1210] and)
        (NP (CD:[1211..1215] 10.5) (NN:[1215..1216] %)))
      (,:[1216..1217] ,)
      (ADVP (RB:[1218..1230] respectively)))
    (.:[1230..1231] .)))

;sentence 11 Span:1232..1370
;In particular, among the adenomas with size lower than  5 mm, K-ras2 mutation
;and DNA aneuploidy frequencies were only slightly above  1%.
;[1257..1265]:malignancy:"adenomas"
;[1294..1300]:gene-rna:"K-ras2"
;[1318..1328]:variation-type:"aneuploidy"
(SENT
  (S
    (PP (IN:[1232..1234] In)
      (NP (JJ:[1235..1245] particular)))
    (,:[1245..1246] ,)
    (PP (IN:[1247..1252] among)
      (NP
        (NP (DT:[1253..1256] the) (NNS:[1257..1265] adenomas))
        (PP (IN:[1266..1270] with)
          (NP (NN:[1271..1275] size)
            (NML
              (QP (JJR:[1276..1281] lower) (IN:[1282..1286] than)
                  (CD:[1288..1289] 5))
              (NN:[1290..1292] mm))))))
    (,:[1292..1293] ,)
    (NP-SBJ
      (NP (NN:[1294..1300] K-ras2) (NN:[1301..1309] mutation)
        (NML-1 (-NONE-:[1309..1309] *P*)))
      (CC:[1310..1313] and)
      (NP (NN:[1314..1317] DNA) (NN:[1318..1328] aneuploidy)
        (NML-1 (NNS:[1329..1340] frequencies))))
    (VP (VBD:[1341..1345] were)
      (ADVP (RB:[1346..1350] only) (RB:[1351..1359] slightly))
      (PP-PRD (IN:[1360..1365] above)
        (NP (CD:[1367..1368] 1) (NN:[1368..1369] %))))
    (.:[1369..1370] .)))

;sentence 12 Span:1371..1502
;Statistically significant correlations were found between K-ras2 and size, 
;DNA ploidy and size and K-ras2 and S-phase (p < 0.001).
;[1429..1435]:gene-rna:"K-ras2"
;[1451..1457]:variation-type:"ploidy"
;[1471..1477]:gene-rna:"K-ras2"
(SENT
  (S
    (NP-SBJ-1
      (ADJP (RB:[1371..1384] Statistically) (JJ:[1385..1396] significant))
      (NNS:[1397..1409] correlations))
    (VP (VBD:[1410..1414] were)
      (VP (VBN:[1415..1420] found)
        (NP-1 (-NONE-:[1420..1420] *))
        (PP (IN:[1421..1428] between)
          (NP
            (NP (NN:[1429..1435] K-ras2) (CC:[1436..1439] and)
                (NN:[1440..1444] size))
            (,:[1444..1445] ,)
            (NP
              (NP (NN:[1447..1450] DNA) (NN:[1451..1457] ploidy))
              (CC:[1458..1461] and)
              (NP (NN:[1462..1466] size)))
            (CC:[1467..1470] and)
            (NP (NN:[1471..1477] K-ras2) (CC:[1478..1481] and)
                (NN:[1482..1489] S-phase))))
        (PRN (-LRB-:[1490..1491] -LRB-)
          (S
            (NP-SBJ (NN:[1491..1492] p))
            (VP (SYM:[1493..1494] <)
              (NP (CD:[1495..1500] 0.001))))
          (-RRB-:[1500..1501] -RRB-))))
    (.:[1501..1502] .)))

;sentence 13 Span:1503..1668
;In particular, among the  wild type K-ras2 adenomas, high S-phase values were
;detected in 8% of the cases  versus 57% among the K-ras2 mutated adenomas (p
;= 0.0005).
;[1539..1545]:gene-rna:"K-ras2"
;[1546..1554]:malignancy:"adenomas"
;[1631..1637]:gene-rna:"K-ras2"
;[1646..1654]:malignancy:"adenomas"
(SENT
  (S
    (PP (IN:[1503..1505] In)
      (NP (JJ:[1506..1516] particular)))
    (,:[1516..1517] ,)
    (PP (IN:[1518..1523] among)
      (NP (DT:[1524..1527] the)
        (NML (JJ:[1529..1533] wild) (NN:[1534..1538] type))
        (NN:[1539..1545] K-ras2) (NNS:[1546..1554] adenomas)))
    (,:[1554..1555] ,)
    (NP-SBJ-1 (JJ:[1556..1560] high) (NN:[1561..1568] S-phase)
              (NNS:[1569..1575] values))
    (VP (VBD:[1576..1580] were)
      (VP (VBN:[1581..1589] detected)
        (NP-1 (-NONE-:[1589..1589] *))
        (PP (IN:[1590..1592] in)
          (NP
            (NP
              (NP (CD:[1593..1594] 8) (NN:[1594..1595] %))
              (PP (IN:[1596..1598] of)
                (NP (DT:[1599..1602] the) (NNS:[1603..1608] cases))))
            (PP (IN:[1610..1616] versus)
              (NP
                (NP (CD:[1617..1619] 57) (NN:[1619..1620] %))
                (PP (IN:[1621..1626] among)
                  (NP (DT:[1627..1630] the) (NN:[1631..1637] K-ras2)
                      (VBN:[1638..1645] mutated) (NNS:[1646..1654] adenomas)))))))
        (PRN (-LRB-:[1655..1656] -LRB-)
          (S
            (NP-SBJ (NN:[1656..1657] p))
            (VP (SYM:[1658..1659] =)
              (NP (CD:[1660..1666] 0.0005))))
          (-RRB-:[1666..1667] -RRB-))))
    (.:[1667..1668] .)))

;sentence 14 Span:1669..1831
;The present series of  FAP adenomas indicates that K-ras2 activation and
;gross genomic changes play a  role toward a proliferative gain and tumour
;growth in size.
;[1692..1704]:malignancy:"FAP adenomas"
;[1720..1726]:gene-rna:"K-ras2"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1669..1672] The) (JJ:[1673..1680] present)
          (NN:[1681..1687] series))
      (PP (IN:[1688..1690] of)
        (NP (NN:[1692..1695] FAP) (NNS:[1696..1704] adenomas))))
    (VP (VBZ:[1705..1714] indicates)
      (SBAR (IN:[1715..1719] that)
        (S
          (NP-SBJ
            (NP (NN:[1720..1726] K-ras2) (NN:[1727..1737] activation))
            (CC:[1738..1741] and)
            (NP (JJ:[1742..1747] gross) (JJ:[1748..1755] genomic)
                (NNS:[1756..1763] changes)))
          (VP (VBP:[1764..1768] play)
            (NP
              (NP (DT:[1769..1770] a) (NN:[1772..1776] role))
              (PP (IN:[1777..1783] toward)
                (NP
                  (NP
                    (NP (DT:[1784..1785] a) (JJ:[1786..1799] proliferative)
                        (NN:[1800..1804] gain))
                    (CC:[1805..1808] and)
                    (NP (NN:[1809..1815] tumour) (NN:[1816..1822] growth)))
                  (PP (IN:[1823..1825] in)
                    (NP (NN:[1826..1830] size))))))))))
    (.:[1830..1831] .)))

;section 15 Span:1835..1880
;PMID: 10661623 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1835..1839] PMID) (::[1839..1840] :) (CD:[1841..1849] 10661623)
        (IN:[1850..1851] -LSB-) (NNP:[1851..1857] PubMed) (HYPH:[1858..1859] -)
        (JJ:[1860..1867] indexed) (IN:[1868..1871] for)
        (NNP:[1872..1880] MEDLINE-RSB-)))
